Effects of Timolol Treatment on Pancreatic Antioxidant Enzymes in Streptozotocin-induced Diabetic Rats: An Experimental and Computational Study.
6-phosphogluconate dehydrogenase
cAMP
diabetes
glucose-6-phosphate dehydrogenase
timolol
Journal
Journal of medical biochemistry
ISSN: 1452-8258
Titre abrégé: J Med Biochem
Pays: Serbia
ID NLM: 101315490
Informations de publication
Date de publication:
Jul 2019
Jul 2019
Historique:
received:
28
07
2018
accepted:
18
09
2018
entrez:
4
6
2019
pubmed:
4
6
2019
medline:
4
6
2019
Statut:
epublish
Résumé
The study aimed to investigate whether timolol-treatment has a beneficial effect on pentose phosphate pathway enzyme activities such as glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6PGDH) enzyme activities and cAMP level in streptozotocin-induced diabetic rats in pancreatic tissues. Diabetes was induced by streptozotocin (STZ) in 3-month old male Wistar rats. The diabetic rats were treated with timolol (5 mg/kg body weight, for 12 weeks) while the control group received saline. Enzyme activities were determined in pancreas tissue. To support our results, we performed Timolol treatment of STZ-induced diabetic rats had no noteworthy effect on high blood-glucose levels. However, this treatment induced activities of G6PD and 6PGDH in diabetic rats. Timolol treatment significantly increased cAMP level in diabetic pancreatic tissue. We found that timolol cannot bind strongly to either G6PD or 6PGD, but there is a relatively higher binding affinity to adenylyl cyclase, responsible for cAMP production, serving as a regulatory signal via specific cAMP-binding proteins. Our data point out that timolol treatment has beneficial effects on the antioxidant defence mechanism enzymes in the pancreas of STZ-induced diabetic rats. Cilj istraživanja je bio da se utvrdi da li tretman timololom ima pozitivan efekat na aktivnosti enzima pentoze fosfata, kao što su aktivnosti glukoze-6-fosfat dehidrogenaze (G6PD), enzimske aktivnosti 6-fosfoglukonat dehidrogenaze i cAMP nivo u tkivu pankreasa kod pacova kojima je dijabetes izazvan streptozotocionom. Dijabetes je izazvan streptozotocionom (STZ) kod tromesečnih mužjaka vistar pacova. Pacovi sa dijabetesom su tretirani timololom (5 mg/kg telesne težine tokom 12 nedelja), dok je kontrolna grupa primila fiziološki rastvor. Enzimske aktivnosti su utvrđivane u tkivu pankreasa. Da bismo potkrepili naše rezultate, sproveli smo Tretman timololom na pacovima kojima je dijabetes izazvan putem STZ-a nije imao značajan uticaj na visoke nivoe glukoze u krvi. Međutim, kod takvih pacova ovaj tretman je indukovao aktivnosti G6PD i 6PGDH. Lečenje timololom značajno je povećalo nivo cAMP-a u dijabetičnom tkivu pankreasa. Utvrdili smo da se timolol ne može snažno vezati ni za G6PD, ni za 6PGD, ali da postoji relativno veći afinitet vezivanja za adenilil ciklazu, odgovornu za proizvodnju cAMP, koja služi kao regulatorni signal putem određenih cAMP vezivnih proteina. Naši podaci ukazuju da tretman timololom ima pozitivne efekte na antioksidantne enzime odbrambenog sistema u pankreasu pacova sa dijebetesom izazvanim putem STZ-a.
Sections du résumé
BACKGROUND
BACKGROUND
The study aimed to investigate whether timolol-treatment has a beneficial effect on pentose phosphate pathway enzyme activities such as glucose-6-phosphate dehydrogenase (G6PD), 6-phosphogluconate dehydrogenase (6PGDH) enzyme activities and cAMP level in streptozotocin-induced diabetic rats in pancreatic tissues.
METHODS
METHODS
Diabetes was induced by streptozotocin (STZ) in 3-month old male Wistar rats. The diabetic rats were treated with timolol (5 mg/kg body weight, for 12 weeks) while the control group received saline. Enzyme activities were determined in pancreas tissue. To support our results, we performed
RESULTS
RESULTS
Timolol treatment of STZ-induced diabetic rats had no noteworthy effect on high blood-glucose levels. However, this treatment induced activities of G6PD and 6PGDH in diabetic rats. Timolol treatment significantly increased cAMP level in diabetic pancreatic tissue. We found that timolol cannot bind strongly to either G6PD or 6PGD, but there is a relatively higher binding affinity to adenylyl cyclase, responsible for cAMP production, serving as a regulatory signal via specific cAMP-binding proteins.
CONCLUSIONS
CONCLUSIONS
Our data point out that timolol treatment has beneficial effects on the antioxidant defence mechanism enzymes in the pancreas of STZ-induced diabetic rats.
UVOD
UNASSIGNED
Cilj istraživanja je bio da se utvrdi da li tretman timololom ima pozitivan efekat na aktivnosti enzima pentoze fosfata, kao što su aktivnosti glukoze-6-fosfat dehidrogenaze (G6PD), enzimske aktivnosti 6-fosfoglukonat dehidrogenaze i cAMP nivo u tkivu pankreasa kod pacova kojima je dijabetes izazvan streptozotocionom.
METODE
METHODS
Dijabetes je izazvan streptozotocionom (STZ) kod tromesečnih mužjaka vistar pacova. Pacovi sa dijabetesom su tretirani timololom (5 mg/kg telesne težine tokom 12 nedelja), dok je kontrolna grupa primila fiziološki rastvor. Enzimske aktivnosti su utvrđivane u tkivu pankreasa. Da bismo potkrepili naše rezultate, sproveli smo
REZULTATI
UNASSIGNED
Tretman timololom na pacovima kojima je dijabetes izazvan putem STZ-a nije imao značajan uticaj na visoke nivoe glukoze u krvi. Međutim, kod takvih pacova ovaj tretman je indukovao aktivnosti G6PD i 6PGDH. Lečenje timololom značajno je povećalo nivo cAMP-a u dijabetičnom tkivu pankreasa. Utvrdili smo da se timolol ne može snažno vezati ni za G6PD, ni za 6PGD, ali da postoji relativno veći afinitet vezivanja za adenilil ciklazu, odgovornu za proizvodnju cAMP, koja služi kao regulatorni signal putem određenih cAMP vezivnih proteina.
ZAKLJUČAK
UNASSIGNED
Naši podaci ukazuju da tretman timololom ima pozitivne efekte na antioksidantne enzime odbrambenog sistema u pankreasu pacova sa dijebetesom izazvanim putem STZ-a.
Autres résumés
Type: Publisher
(srp)
Cilj istraživanja je bio da se utvrdi da li tretman timololom ima pozitivan efekat na aktivnosti enzima pentoze fosfata, kao što su aktivnosti glukoze-6-fosfat dehidrogenaze (G6PD), enzimske aktivnosti 6-fosfoglukonat dehidrogenaze i cAMP nivo u tkivu pankreasa kod pacova kojima je dijabetes izazvan streptozotocionom.
Identifiants
pubmed: 31156341
doi: 10.2478/jomb-2018-0034
pii: jomb-2018-0034
pmc: PMC6534949
doi:
Types de publication
Journal Article
Langues
eng
Pagination
306-316Déclaration de conflit d'intérêts
Conflict of interest Conflict of interest statement: The authors stated that they have no conflicts of interest regarding the publication of this article.
Références
Free Radic Biol Med. 1988;5(2):113-24
pubmed: 3075947
Diabetes. 1969 Dec;18(12):797-819
pubmed: 4311899
Folia Biol (Praha). 2009;55(1):11-6
pubmed: 19445841
World Health Organ Tech Rep Ser. 1967;366:1-53
pubmed: 4963040
Exp Clin Endocrinol Diabetes. 2016 May;124(5):263-75
pubmed: 27219686
Gen Physiol Biophys. 2004 Sep;23(3):347-55
pubmed: 15638122
J Med Biochem. 2018 Jul 01;37(3):373-378
pubmed: 30598635
J Neurosci. 2014 Jul 9;34(28):9281-9
pubmed: 25009261
Am J Physiol Renal Physiol. 2005 Nov;289(5):F1040-7
pubmed: 15956780
Horm Metab Res. 2012 Dec;44(13):938-42
pubmed: 23015612
Bioorg Med Chem. 2006 Jul 1;14(13):4568-77
pubmed: 16510286
J Diet Suppl. 2016;13(3):339-51
pubmed: 26317558
Biochim Biophys Acta. 2016 Dec;1866(2):232-251
pubmed: 27681874
J Biol Chem. 1951 Nov;193(1):265-75
pubmed: 14907713
Proc Natl Acad Sci U S A. 2014 Mar 11;111(10):3727-32
pubmed: 24567411
J Ethnopharmacol. 2012 Oct 31;144(1):101-8
pubmed: 22960550
Biochimie. 2005 Feb;87(2):187-90
pubmed: 15760711
Diabetes. 2016 Sep;65(9):2624-38
pubmed: 27284106
Pharm Biol. 2017 Dec;55(1):510-515
pubmed: 27937081
J Biol Chem. 1975 Jun 25;250(12):4575-9
pubmed: 166996
Curr Protoc Pharmacol. 2015 Sep 01;70:5.47.1-5.47.20
pubmed: 26331889
IUBMB Life. 2012 May;64(5):362-9
pubmed: 22431005
Cardiovasc Toxicol. 2010 Jun;10(2):73-86
pubmed: 20458637
Biol Trace Elem Res. 2005 Summer;105(1-3):135-50
pubmed: 16034159
Curr Opin Nephrol Hypertens. 2017 Jan;26(1):43-49
pubmed: 27755120
Mol Aspects Med. 2001 Dec;22(6):247-84
pubmed: 11890977
Headache. 1987 Feb;27(2):84-6
pubmed: 3553070
World J Diabetes. 2016 Jan 10;7(1):1-7
pubmed: 26788261
Structure. 2000 Mar 15;8(3):293-303
pubmed: 10745013
Br J Clin Pharmacol. 1996 Aug;42(2):217-23
pubmed: 8864321
Med Hypotheses. 2015 Aug;85(2):219-23
pubmed: 26004559
FASEB J. 2010 May;24(5):1497-505
pubmed: 20032314
Diabetes Care. 1983 May-Jun;6(3):285-90
pubmed: 6347581
Biochim Biophys Acta. 2014 Dec;1842(12 Pt B):2584-92
pubmed: 25064591
Proc Natl Acad Sci U S A. 1975 Nov;72(11):4381-4
pubmed: 172907
Physiol Int. 2016 Mar;103(1):49-64
pubmed: 27030627
J Struct Biol. 2010 Jan;169(1):25-35
pubmed: 19686854
Clin Ophthalmol. 2008 Mar;2(1):15-20
pubmed: 19668385
Mol Cell Biochem. 2007 Oct;304(1-2):255-63
pubmed: 17530185
Sci Rep. 2017 Jan 09;7:39604
pubmed: 28067255
Mol Cell Biochem. 2014 Oct;395(1-2):177-86
pubmed: 24947049
Mol Metab. 2016 Sep 09;5(11):1083-1091
pubmed: 27818934
Science. 1973 Feb 9;179(4073):569-71
pubmed: 4346825
Phys Ther. 2008 Nov;88(11):1322-35
pubmed: 18801863
Diabetes. 2017 Jan;66(1):193-205
pubmed: 27737949
Nat Cell Biol. 2015 Nov;17(11):1484-96
pubmed: 26479318
Methods Enzymol. 1975;41:220-6
pubmed: 1128263
PLoS One. 2013 Jul 29;8(7):e71014
pubmed: 23923043
Science. 1979 Oct 12;206(4415):225-7
pubmed: 225798